| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | salbutamol sulphate (Salbulin MDPI Novolizer®) |
| Formulation | 100 micrograms/dose inhalation powder |
| Reference number | 269 |
| Indication | Treatment of patients aged 6 years and over with reversible airway obstruction, such as asthma, for the relief and prevention of asthma symptoms
|
| Company | Meda Pharmaceuticals Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 06/05/2008 |